RIGHTLINE SPECIAL REPORTS - NEW!

Every so often a unique stock with extraordinarily high investment potential shows up on our radar. This special new product features eight to ten high impact reports a year on companies and markets that are poised for explosive growth and are certain to dramatically influence people's lives all around the globe. Below is more information on our introductory Special Report.

November 11, 2003

Hello,

I'd like to tell you about a small company in California that recently introduced an amazing cancer treatment technology that is literally curing patients in hundreds of hospitals around the globe.

This revolutionary process is quickly changing the way cancerous tumors are routinely treated, and will very likely replace current radiation therapy for most forms of cancer within the next few years.

Having witnessed firsthand the effects of this disease and the side effects of conventional treatment with my father and grandfather during the past 15-years, I was astounded to find out about the tremendous advances in therapy that have been made recently.

Also, as the editor of an investment service, I want to show you what this unique company is doing for their shareholders, as well as for their patients.

Please read the important information below - you certainly won't regret it!

Thomas Sutton, Editor
Pro RightLine Corp
Round Rock, Texas
http://www.rightline.net
PH: 800-737-4518

"With knowledge comes opportunity, with opportunity comes success." ~ Anon

For the past several months an obscure medical technology company has been aggressively buying it's own shares on the open market. Why? Part of the answer can be found in the recently announced record-breaking earnings and sales numbers for the third quarter of 2003. Annual revenue just topped $1-Billion, and the firm has another $800-Million in back orders waiting to be filled. Profits for the past fiscal year rose almost 20% to an impressive $130 million, and corporate executives just raised the earnings and sales outlook for 2004.

Not only is the company doing extremely well, shareholders have also made huge profits as the company stock soared over 600% during the past few years, and most of that increase occurred during the worst bear market in decades. Those who own the stock have essentially held a winning lottery ticket, with all indications that the best is yet to come.

More than 1,000,000 people are diagnosed with cancer every year. Sadly, over 1500 die from the disease each day. Fortunately, this company is making a dramatic positive impact on these statistics. It isn't a drug company that has to wait years and jump through endless government requirements for approval. In fact, this revolutionary technology is already curing cancerous tumors in over 450 hospitals around the globe.

The number of medical facilities offering this technique has more than doubled in each of the last five years, and hundreds of other centers are equipping themselves with the capability. Investors who own this stock are positioned for the opportunity of a lifetime.

Here's what doctors have to say:

~ Soren Bentzen, Ph.D., head of biostatistics at the Gray Laboratory Cancer Research Trust in London predicted In 2002 that this new technology will replace conventional radiation therapy for most forms of cancer in the next five years.

~ Dr. Patrick Swift, medical director, radiation oncology at Alta Bates Comprehensive Cancer Center in Berkeley, California treated his first patient with the new technology in October 2001, "and now all of our prostate cancer patients are on it."

~ Richard Emery, chief medical physicist and director of radiation services at St. Vincent's Cancer Center in New York says "It's deeply satisfying to have a technology that can be curative without the side effects associated with conventional therapy."

~ Professor James D. Cox, MD, heads the Division of Radiation Oncology at the University of Texas Anderson Cancer Center. He reports that his staff now treats nearly 1000 patients each year with the new technology, and " . . . it is very much a part of our future."·

~Dr. Ted Lawrence, Professor of Oncology at the University of Michigan, believes this breakthrough technology has opened up "extraordinary possibilities."

Although doctors are quickly becoming familiar with the benefits of this amazing cancer treatment, most investors are still unaware of it. Very few Wall Street analysts even follow the stock. However, it won't be long until the national media realizes the astounding health and investment potential of this obscure company, then it should quickly move it off the sidelines and onto center stage.

Once the general public becomes aware that this technology has an extremely high success rate treating cancerous tumors, investors around the world will want to buy shares in the company. Frankly, there is no way to know how high the stock will go.

It won't be long until cancer patients all over the globe will be asking for this treatment. This alone will ignite worldwide interest in the stock and is the central reason why we are letting you know about it now.

This stock meets my criteria for an optimum potential opportunity. It offers state of the art technology, exceptional revenue growth, tremendous profits, and a vast untapped market for its products. This could very well be the best stock opportunity of the decade. Not only does this investment offer life changing financial potential, the technology behind it offers life-changing treatment to thousands of cancer patients. It's a win-win opportunity!

Despite the firm's huge profits, it has no real competition. That's because the company sells a highly advanced sophisticated system that uses digital technology to shoot powerful radiation rays at the cancer. While standard radiation therapy often damages healthy tissue and organs located near the tumor, this company's products deliver precise beams directly to the specific diseased areas, avoiding unnecessary damage to healthy tissue and organs. The degree of complexity required to design and develop this type system combined with the extremely high cost of tooling up for production makes it extremely unlikely that any new competitors will show up any time soon.

The extremely high rate of earnings growth places this firm near the top of all public companies, and the $800 Million backlog of orders means things are about to get even better. Let's put this extraordinary opportunity in perspective. Occasionally - maybe once every decade - a company shows up on the radar that is not only outrageously successful, but also dramatically impacts the way business is done in the world. Wal-Mart and Microsoft are two prime examples. Many early investors rode these stocks to stratospheric financial gains, completely transforming their lives!

Do you remember a few years ago when Qualcomm (QCOM) rose from obscurity to become the best performing stock in America? Fortunately RightLine readers were aware of this superb telecom stock while it was still on the launch pad - way before it rocketed into profit history. From where we sit, this cancer-fighting firm has similar investment potential.

Our services at Pro RightLine are unique. Unlike many firms on Wall Street, we don't accept fees or any other financial incentives from companies to promote their stock. We don't do investment-banking deals with companies we recommend, nor do we have any other associations that might be considered a conflict of interest. Our only commitment is to our subscribers, many of whom have been with us since we began with our first RightLine Split Report in 1997.

No one can predict the future with absolute certainty, but one fact is for sure - you can't win if you don't put a few dollars on the table. Knowledge is the key to successful investments, so take advantage of this great opportunity today and receive everything you need to know about the most innovative technology in the history of cancer treatment.

It's all contained in a RightLine Special Report that you can purchase for only $79.95, or with an annual subscription to RightLine Special Reports for only $389.95.

This is an incredible opportunity for anyone interested in making money in the stock market. So access this page to buy your copy of this Special Report. Take me there now!

Thanks!

Thomas Sutton, Editor
The RightLine Report